Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit
Avenue Therapeutics, Inc. (Nasdaq: ATXI), a specialty pharmaceutical company focusing on neurologic disease treatments, has announced its participation in Maxim Group's 2024 Healthcare Virtual Summit. The company's CEO, Alexandra MacLean, M.D., will engage in a fireside chat on Tuesday, October 15, 2024, at 1:30 PM ET.
The event will be accessible to registered attendees, and investors can sign up or log in to the conference through a provided link. This participation highlights Avenue Therapeutics' commitment to engaging with the investment community and sharing insights about their developments in the neurologic disease treatment sector.
Avenue Therapeutics, Inc. (Nasdaq: ATXI), un'azienda farmaceutica specializzata nel trattamento delle malattie neurologiche, ha annunciato la sua partecipazione al Maxim Group's 2024 Healthcare Virtual Summit. L'amministratore delegato dell'azienda, Alexandra MacLean, M.D., parteciperà a una chiacchierata informale martedì, 15 ottobre 2024, alle 13:30 ET.
L'evento sarà accessibile ai partecipanti registrati, e gli investitori potranno iscriversi o accedere alla conferenza tramite un link fornito. Questa partecipazione sottolinea l'impegno di Avenue Therapeutics nel dialogo con la comunità degli investitori e nella condivisione di informazioni sui loro progressi nel settore del trattamento delle malattie neurologiche.
Avenue Therapeutics, Inc. (Nasdaq: ATXI), una empresa farmacéutica especializada en tratamientos para enfermedades neurológicas, ha anunciado su participación en el Maxim Group's 2024 Healthcare Virtual Summit. La directora ejecutiva de la empresa, Alexandra MacLean, M.D., participará en una charla informal el martes 15 de octubre de 2024, a la 1:30 PM ET.
El evento estará accesible para los asistentes registrados, y los inversores podrán registrarse o iniciar sesión en la conferencia a través de un enlace proporcionado. Esta participación resalta el compromiso de Avenue Therapeutics con la comunidad inversora y la compartición de insights sobre sus desarrollos en el sector del tratamiento de enfermedades neurológicas.
Avenue Therapeutics, Inc. (Nasdaq: ATXI), 신경계 질환 치료에 주력하는 전문 제약 회사, Maxim Group의 2024 Healthcare Virtual Summit에 참여한다고 발표했습니다. 회사의 CEO인 Alexandra MacLean, M.D.는 2024년 10월 15일 화요일, 동부 시간으로 오후 1시 30분에 화상 대담에 참여할 예정입니다.
이번 행사는 등록한 참석자에게 접근 가능하며, 투자자들은 제공된 링크를 통해 회의에 등록하거나 로그인할 수 있습니다. 이 참여는 Avenue Therapeutics가 투자 커뮤니티와 소통하고 신경계 질환 치료 분야의 발전에 대한 통찰을 공유하는 데 전념하고 있음을 강조합니다.
Avenue Therapeutics, Inc. (Nasdaq: ATXI), une entreprise pharmaceutique spécialisée dans les traitements des maladies neurologiques, a annoncé sa participation au Maxim Group's 2024 Healthcare Virtual Summit. La PDG de l'entreprise, Alexandra MacLean, M.D., prendra part à une discussion informelle le mardi 15 octobre 2024, à 13h30 ET.
L'événement sera accessible aux participants enregistrés, et les investisseurs pourront s'inscrire ou se connecter à la conférence via un lien fourni. Cette participation souligne l'engagement d'Avenue Therapeutics à interagir avec la communauté des investisseurs et à partager des perspectives sur ses développements dans le secteur des traitements des maladies neurologiques.
Avenue Therapeutics, Inc. (Nasdaq: ATXI), ein spezialisiertes Pharmaunternehmen, das sich auf die Behandlung neurologischer Erkrankungen konzentriert, hat seine Teilnahme am Maxim Group's 2024 Healthcare Virtual Summit angekündigt. Die CEO des Unternehmens, Alexandra MacLean, M.D., wird am Dienstag, den 15. Oktober 2024, um 13:30 Uhr ET an einem informellen Gespräch teilnehmen.
Die Veranstaltung wird für registrierte Teilnehmer zugänglich sein, und Investoren können sich über einen bereitgestellten Link für die Konferenz anmelden oder einloggen. Diese Teilnahme unterstreicht das Engagement von Avenue Therapeutics, mit der Investoren-Community zu interagieren und Einblicke in ihre Entwicklungen im Bereich der Behandlung neurologischer Erkrankungen zu teilen.
- None.
- None.
MIAMI, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in a fireside chat at Maxim Group’s 2024 Healthcare Virtual Summit on Tuesday, October 15, 2024 at 1:30 PM ET.
The fireside chat will be available to registered attendees. Investors may sign-up or log-in to the conference here.
About Avenue Therapeutics
Avenue Therapeutics, Inc. (Nasdaq: ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. It is currently developing three assets including AJ201, a first-in-class asset for spinal and bulbar muscular atrophy, BAER-101, an oral small molecule selective GABAA α2, α3 receptor positive allosteric modulator for CNS diseases, and IV tramadol for the management of acute postoperative pain in adults in a medically supervised healthcare setting. Avenue is headquartered in Miami, FL and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, visit www.avenuetx.com.
Contact:
Jaclyn Jaffe
Avenue Therapeutics, Inc.
(781) 652-4500
ir@avenuetx.com
FAQ
When is Avenue Therapeutics (ATXI) participating in Maxim Group's 2024 Healthcare Virtual Summit?
Who will represent Avenue Therapeutics (ATXI) at the Maxim Group's 2024 Healthcare Virtual Summit?
What is the focus of Avenue Therapeutics (ATXI) as a specialty pharmaceutical company?
How can investors attend Avenue Therapeutics' (ATXI) fireside chat at the Maxim Group's 2024 Healthcare Virtual Summit?
